A paper published in April 2026 in Nature Structural and Molecular Biology reported an engineered compact CRISPR editor, Al3Cas12f RKK, that is small enough to package inside an adeno-associated virus vector and produces more efficient editing than predecessor compact editors (Guan et al., last author David Taylor, PMID 41975095). The paper is a platform paper; it does not name sickle cell disease as a target. No in-vivo AAV-CRISPR trial for sickle cell disease is active, recruiting, or enrolling in the US ClinicalTrials.gov registry as of April 2026. Every CRISPR sickle-cell-disease trial in the US registry is ex-vivo: patient stem cells are edited outside the body and returned by infusion after myeloablative chemotherapy.
That distinction explains the gap between the headline and the access reality. The mechanistic advance in Taylor 2026 will matter for the future of in-vivo gene therapy if and when it is applied to sickle cell disease. It has not been applied yet.
What Casgevy and risto-cel actually deliver today
Two ex-vivo CRISPR therapies exist for severe sickle cell disease. Casgevy (exa-cel) reported its pivotal trial result in 2024: 29 of 30 evaluable patients (97 percent, 95 percent CI 83 to 100) free of vaso-occlusive crises for at least 12 consecutive months after treatment (Frangoul et al., NEJM 2024, PMID 38661449; trial NCT03745287). Risto-cel, a base-editing therapy from Beam Therapeutics, reported its 2026 interim analysis: mean on-target edits at 67.4 percent at 6 months, with fetal hemoglobin above 60 percent of total hemoglobin in 13 evaluable patients (Gupta et al., NEJM 2026, PMID 41931046). Both therapies edit the patient's own hematopoietic stem cells outside the body and return them by infusion.
Both also require the same pre-infusion protocol: pharmacokinetically dose-adjusted busulfan myeloablation, delivered at an authorized treatment center. That protocol is the access bottleneck. The size of the editor is not.
The access reality is price, conditioning, and center geography
The Institute for Clinical and Economic Review modeled Casgevy and Lyfgenia in 2023 against common cost-effectiveness thresholds. Its finding: both therapies would meet those thresholds if priced between 1.35 million and 2.05 million dollars per treatment course (ICER 2023 Final Evidence Report). Both are priced at or above the upper end of that range. ICER's public language on the pricing question names the equity stakes directly: US government and US payers carry, in its words, "special obligations to ensure access to these new transformative gene therapies" given sickle cell disease's disproportionate impact on descendants of enslaved Americans.
Price is one layer. Myeloablative conditioning is the second; that protocol destroys the patient's bone marrow and takes weeks of hospitalization to recover from. The third is the geography of authorized treatment centers, which are concentrated in a small number of academic medical centers that may be many hours from a patient's home. An in-vivo AAV-CRISPR therapy, if it existed for sickle cell disease, would shortcut the conditioning step because no stem-cell harvest would be required. No such therapy exists in the clinical-trial registry as of this writing.
The companies in the public conversation do not have an in-vivo SCD pipeline
Intellia Therapeutics, often named as the in-vivo CRISPR company, has no sickle cell disease program on its current pipeline. Intellia's in-vivo platform is liver-targeted: hereditary angioedema, transthyretin amyloidosis, hemophilia B (intelliatx.com/our-pipeline/, retrieved 2026-04-22). Sickle cell disease requires hematopoietic-stem-cell editing, which no in-vivo delivery platform has yet clinically demonstrated. Beam Therapeutics' risto-cel, cited above, is base editing but it is ex-vivo. Editas Medicine paused its reni-cel SCD program.
Naming the actual pipeline matters. The narrative "CRISPR is getting better" has been running for a decade, and Black patients and families who are the ones affected by sickle cell disease have been told repeatedly that the next paper is the one. Reporting that a specific advance does not map to their disease is journalism. Reporting that the next advance is coming is speculation.
100,000 Americans have sickle cell disease. More than 90 percent are Black.
Sickle cell disease affects approximately 100,000 people in the United States. More than 90 percent are non-Hispanic Black or African American. The condition occurs in about 1 of every 365 Black or African American births (CDC Sickle Cell Disease Data and Statistics). Any claim about US CRISPR sickle-cell access is therefore a claim about US Black patient access.
Julie Kanter, MD, director of the Adult Sickle Cell Clinic at the University of Alabama at Birmingham and co-author of the Gupta 2026 risto-cel paper, has been the most public US SCD clinician on the access-equity question (UAB Hematology). Haydar Frangoul, MD, medical director of the Pediatric Hematology/Oncology and Cellular Therapy program at the Children's Hospital at TriStar Centennial in Nashville and principal investigator on the Casgevy pivotal trial, speaks to the trial-investigator side.
How to check which CRISPR SCD trials are enrolling and who to ask about access
Search ClinicalTrials.gov with the filter "condition: Sickle Cell Disease, intervention: CRISPR, status: recruiting" to see the active US trials in real time. That search is the only authoritative source for which trials are currently enrolling.
Two advocacy organizations run patient-side support. Sick Cells runs federal and state public-policy advocacy for the sickle cell community and publishes enrollment and insurance-navigation resources. The Sickle Cell Reproductive Health Education Directive publishes education and screening resources for patients, families, and prospective parents. Ask your treating hematologist about authorized-treatment-center referrals if you have severe sickle cell disease that has not responded to hydroxyurea and transfusion therapy; the named treatment centers are where any of the current ex-vivo therapies can be delivered.
